Analysis of sebum lipid composition and the development of acneiform rash before and after administration of EGFR inhibitor

Takeshi Nakahara, Y. Moroi, K. Takayama, Yoichi Nakanishi, Masutaka Furue

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Treatment with an epidermal growth factor receptor inhibitor (EGFRI) in patients having non-small-cell lung cancer can cause frequent and diverse skin toxicities, an acneiform rash being one of the commonest. Although the exact pathophysiology of this rash and its development mechanisms remain unknown, investigators have noted that EGFRI induced skin toxicity might be partly associated with sebaceous gland function. Sebum is composed mainly of the lipids squalene (SQ), wax ester (WE), triglyceride, free fatty acid, and cholesterol, which are secreted mostly from the sebaceous glands and by keratinocytes. We therefore investigated the lipid composition of sebum before and after administration of EGFRI and whether sebum composition was associated with the development of acneiform rash. To investigate any associated changes in sebum gland activity, we focused especially on alterations in the amounts of SQ and WE, which are secreted solely from the sebaceous glands. In contrast to our expectations, we observed no substantial changes in the lipid composition of sebum before and after administration of EGFRI. Composition varies with the individual; however, the proportion of SQ and WE derived from the sebaceous glands was significantly lower in regions that did not develop acneiform rash than in regions that did. Our results suggest that development of an acneiform rash after administration of EGFRI could be related to sebaceous gland activity. Measurement of the lipid composition of sebum before therapy with EGFRI might predict which patients will be prone to acneiform rash.

Original languageEnglish
Pages (from-to)e124-e127
JournalCurrent Oncology
Volume22
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Sebum
Sebaceous Glands
Exanthema
Epidermal Growth Factor Receptor
Squalene
Lipids
Waxes
Esters
Skin
Keratinocytes
Nonesterified Fatty Acids
Non-Small Cell Lung Carcinoma
Triglycerides
Cholesterol
Research Personnel
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Analysis of sebum lipid composition and the development of acneiform rash before and after administration of EGFR inhibitor. / Nakahara, Takeshi; Moroi, Y.; Takayama, K.; Nakanishi, Yoichi; Furue, Masutaka.

In: Current Oncology, Vol. 22, No. 2, 01.01.2015, p. e124-e127.

Research output: Contribution to journalArticle

@article{0fd7499e9476458ba7a685c58a679ada,
title = "Analysis of sebum lipid composition and the development of acneiform rash before and after administration of EGFR inhibitor",
abstract = "Treatment with an epidermal growth factor receptor inhibitor (EGFRI) in patients having non-small-cell lung cancer can cause frequent and diverse skin toxicities, an acneiform rash being one of the commonest. Although the exact pathophysiology of this rash and its development mechanisms remain unknown, investigators have noted that EGFRI induced skin toxicity might be partly associated with sebaceous gland function. Sebum is composed mainly of the lipids squalene (SQ), wax ester (WE), triglyceride, free fatty acid, and cholesterol, which are secreted mostly from the sebaceous glands and by keratinocytes. We therefore investigated the lipid composition of sebum before and after administration of EGFRI and whether sebum composition was associated with the development of acneiform rash. To investigate any associated changes in sebum gland activity, we focused especially on alterations in the amounts of SQ and WE, which are secreted solely from the sebaceous glands. In contrast to our expectations, we observed no substantial changes in the lipid composition of sebum before and after administration of EGFRI. Composition varies with the individual; however, the proportion of SQ and WE derived from the sebaceous glands was significantly lower in regions that did not develop acneiform rash than in regions that did. Our results suggest that development of an acneiform rash after administration of EGFRI could be related to sebaceous gland activity. Measurement of the lipid composition of sebum before therapy with EGFRI might predict which patients will be prone to acneiform rash.",
author = "Takeshi Nakahara and Y. Moroi and K. Takayama and Yoichi Nakanishi and Masutaka Furue",
year = "2015",
month = "1",
day = "1",
doi = "10.3747/co.22.2283",
language = "English",
volume = "22",
pages = "e124--e127",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "2",

}

TY - JOUR

T1 - Analysis of sebum lipid composition and the development of acneiform rash before and after administration of EGFR inhibitor

AU - Nakahara, Takeshi

AU - Moroi, Y.

AU - Takayama, K.

AU - Nakanishi, Yoichi

AU - Furue, Masutaka

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Treatment with an epidermal growth factor receptor inhibitor (EGFRI) in patients having non-small-cell lung cancer can cause frequent and diverse skin toxicities, an acneiform rash being one of the commonest. Although the exact pathophysiology of this rash and its development mechanisms remain unknown, investigators have noted that EGFRI induced skin toxicity might be partly associated with sebaceous gland function. Sebum is composed mainly of the lipids squalene (SQ), wax ester (WE), triglyceride, free fatty acid, and cholesterol, which are secreted mostly from the sebaceous glands and by keratinocytes. We therefore investigated the lipid composition of sebum before and after administration of EGFRI and whether sebum composition was associated with the development of acneiform rash. To investigate any associated changes in sebum gland activity, we focused especially on alterations in the amounts of SQ and WE, which are secreted solely from the sebaceous glands. In contrast to our expectations, we observed no substantial changes in the lipid composition of sebum before and after administration of EGFRI. Composition varies with the individual; however, the proportion of SQ and WE derived from the sebaceous glands was significantly lower in regions that did not develop acneiform rash than in regions that did. Our results suggest that development of an acneiform rash after administration of EGFRI could be related to sebaceous gland activity. Measurement of the lipid composition of sebum before therapy with EGFRI might predict which patients will be prone to acneiform rash.

AB - Treatment with an epidermal growth factor receptor inhibitor (EGFRI) in patients having non-small-cell lung cancer can cause frequent and diverse skin toxicities, an acneiform rash being one of the commonest. Although the exact pathophysiology of this rash and its development mechanisms remain unknown, investigators have noted that EGFRI induced skin toxicity might be partly associated with sebaceous gland function. Sebum is composed mainly of the lipids squalene (SQ), wax ester (WE), triglyceride, free fatty acid, and cholesterol, which are secreted mostly from the sebaceous glands and by keratinocytes. We therefore investigated the lipid composition of sebum before and after administration of EGFRI and whether sebum composition was associated with the development of acneiform rash. To investigate any associated changes in sebum gland activity, we focused especially on alterations in the amounts of SQ and WE, which are secreted solely from the sebaceous glands. In contrast to our expectations, we observed no substantial changes in the lipid composition of sebum before and after administration of EGFRI. Composition varies with the individual; however, the proportion of SQ and WE derived from the sebaceous glands was significantly lower in regions that did not develop acneiform rash than in regions that did. Our results suggest that development of an acneiform rash after administration of EGFRI could be related to sebaceous gland activity. Measurement of the lipid composition of sebum before therapy with EGFRI might predict which patients will be prone to acneiform rash.

UR - http://www.scopus.com/inward/record.url?scp=84928253585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928253585&partnerID=8YFLogxK

U2 - 10.3747/co.22.2283

DO - 10.3747/co.22.2283

M3 - Article

VL - 22

SP - e124-e127

JO - Current Oncology

JF - Current Oncology

SN - 1198-0052

IS - 2

ER -